by CytoPrevent | Sep 26, 2022 | What’s new on CytoPrevent
Seth Eisenberg (Professional Practice Coordinator, Infusion Services, Seattle Cancer Care Alliance) Hazardous Drugs Risks associated with exposure to hazardous drugs (HDs) such as chemotherapy, have been well doc-umented over the past two decades and...
by CytoPrevent | Aug 31, 2022 | What’s new on CytoPrevent
ISOPP Standards for the Safe Handling of Cytotoxics Since the initial release of the International Society of Oncology Pharmacy Practitioners (ISOPP) Standards for the Safe Handling of Cytotoxic Drugs in 2007, much has evolved in oncology pharmacy. Safe...
by CytoPrevent | Jun 23, 2022 | Studies
Seth Eisenberg British Journal of Nursing (BJN), 2022, Vol 31, No 10 (Oncology Supplement) ABSTRACT Exposure to cytotoxic chemotherapy can result in acute and chronic conditions including nausea, headaches, rashes, miscarriages, infertility and genetic...
by CytoPrevent | Jan 11, 2022 | What’s new on CytoPrevent
Press Release of the European Parliament On 9 December 2021, Parliament’s Special Committee on Beating Cancer adopted its final proposals on how to strengthen the EU’s role in the fight against cancer. They include the following: 1. Taking stronger EU...
by CytoPrevent | Dec 30, 2021 | What’s new on CytoPrevent
Press Release – 16 December 2021 The Stop Cancer at Work Campaign today welcomes the provisional political agreement by the European Parliament and European Council to include for the first time greater protection and reference to reprotoxic substances...